The biotech calendar was dominated by regulatory and clinical milestones today, with a UK glioblastoma trial moving into its dosing phase, two AstraZeneca oncology assets clearing European regulatory hurdles, and smaller diagnostics and oncology names advancing pivotal programmes. The tape reflected the mixed reality of clinical-stage investing: encouraging trial news lifted several small caps even as PureTech Health slipped despite a genuine regulatory win.
Crism Therapeutics doses first patients in Phase 2 glioblastoma trial
Crism Therapeutics Corporation (AIM:CRTX), the UK clinical-stage drug delivery company building localised chemotherapy treatments, has begun recruiting patients into a registration-grade Phase 2 trial of irinotecan-ChemoSeed in resectable glioblastoma, with dosing starting on 27 August. The milestone caps a period of heavy investment in the company's ChemoSeed platform, an implantable, biodegradable system designed to deliver chemotherapy directly into tumour tissue rather than systemically, and comes as shares in the company edged up 2.13% to 11.49p.
The two-part study will first assess dose escalation in recurrent glioblastoma before moving to evaluate progression-free survival in newly diagnosed patients. That clinical progress arrived alongside a widening of losses, with Crism posting a £1.413 million deficit for the six months to 30 June, up from £0.93 million a year earlier, as administration costs climbed to £1.52 million including £956,000 of research and development spend. The company funded the push with a £2.745 million oversubscribed placing and retail offer in May, plus an £896,088 Innovate UK grant and a £99,902 Invest Northern Ireland grant, leaving cash of £2.269 million at period end, up from £1.128 million at the start of the year, and net cash of £1.9 million as of 18 September.
"This designation significantly enhances the commercial profile of irinotecan-ChemoSeed and establishes a supportive framework for international regulatory engagement," said Andrew Webb, Chief Executive of Crism Therapeutics.
The FDA's decision to grant orphan drug designation to irinotecan-ChemoSeed during the period is the more consequential development for the investment case than the widened loss line. Orphan status carries up to seven years of US market exclusivity upon approval, a valuable commercial shield for a company whose entire proposition rests on a single delivery platform reaching pivotal data. With Charles Spicer joining as Non-Executive Chair from 1 October, Crism now has both the regulatory tailwind and boardroom continuity to carry it through a trial that could define whether ChemoSeed becomes a genuine treatment paradigm or remains a promising but unproven technology.
AstraZeneca's gefurulimab wins CHMP backing for gMG
AstraZeneca (LSE:AZN), up 0.77% at 12,596p, saw its rare disease unit Alexion secure a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for Klygefa (gefurulimab), an add-on treatment for adults with generalised myasthenia gravis who test positive for anti-acetylcholine receptor antibodies. If approved, Klygefa would become the first and only dual-binding nanobody C5 inhibitor available to this patient group in the EU, offering once-weekly subcutaneous self-administration for a rare autoimmune disorder affecting an estimated 82,500 people across Germany, France, the UK, Italy and Spain, of whom 66,000 are antibody-positive.
The opinion rests on the Phase III PREVAIL trial, which enrolled 260 patients across 20 countries and met its primary endpoint, delivering a 1.6-point treatment difference on the Myasthenia Gravis Activities of Daily Living scale at week 26 versus placebo, a result significant at p<0.0001. "With this positive CHMP opinion patients may soon have the option of a novel treatment option that could help them spend less time thinking about their care and more time living their lives," said Tobias Ruck, director at Ruhr-University Bochum's Bergmannsheil.
A self-administered, once-weekly option would meaningfully lower the treatment burden for a disease Alexion chief executive Marc Dunoyer described as one where "unpredictable symptoms can quickly become incapacitating or life-threatening." For AstraZeneca, the win extends Alexion's rare disease franchise into a new mechanism class, reinforcing the unit's role as a growth engine even as the wider group trades on a broadly flat day.
Verici Dx sets Q4 launch for transplant gene test
Verici Dx (LSE:VRCI), the AIM-listed diagnostics developer focused on organ transplant care, will launch its TranscripTx test in the fourth quarter of 2026, sending shares up 11.11% to 0.25p. The test identifies genetic variants known to influence how transplant recipients respond to therapy and their long-term risk of graft failure, using next-generation sequencing to analyse variants in peripheral blood RNA, and will be offered as a laboratory developed test through Verici's CLIA-certified, CAP-accredited laboratory.
The company positions TranscripTx as the only multi-gene panel developed specifically for transplant recipients, built on AI-enabled gene selection and able to detect clinically relevant splice variants that cell-free DNA technologies miss. "This launch translates our robust data repository into a tangible, multi-gene asset that will push the boundaries of precision medicine," Sara Barrington, chief executive of Verici Dx, who, added that the test is "translating cutting-edge RNA science into actionable intelligence" for the research community.
The launch matters because it converts Verici's accumulated clinical data and biological sample repository, built over years of RNA diagnostics work, into a commercial product rather than a research asset. For a company of Verici's scale, a fourth-quarter revenue event tied to a differentiated technical claim gives the market a concrete catalyst to price against, rather than relying solely on pipeline promise.
PureTech's Gallop wins FDA Fast Track for LYT-200
PureTech Health (LSE:PRTC), the hub-and-spoke biotherapeutics company, said its Founded Entity Gallop Oncology has completed a successful End-of-Phase 1 meeting with the FDA for LYT-200, which the regulator has granted Fast Track designation in combination with a hypomethylating agent for relapsed/refractory high-risk myelodysplastic syndromes. Shares in PureTech fell 6.06% to 124p despite the regulatory progress, a reminder that clinical milestones do not always move the tape in the expected direction.
The designation clears the path to STRIDE-MDS, a randomised, double-blind Phase 2 trial enrolling roughly 125 patients split 2:2:1 between two LYT-200 doses plus a hypomethylating agent and a placebo arm. "Our productive End-of-Phase 1 meeting with the U.S. FDA provides a clear path to advance LYT-200 into Phase 2 development," said Eric Elenko, chief executive of Gallop Oncology. LYT-200 targets galectin-9, a protein PureTech describes as both an oncogenic driver and immunosuppressor, and takes a mutation-agnostic approach intended to reach a broader patient population than genetically targeted therapies.
PureTech intends to raise external capital in the first half of 2027 to fund STRIDE-MDS through completion via Gallop Oncology, meaning today's regulatory clearance is really a funding catalyst in waiting rather than a fully resourced programme. The share price move suggests the market is looking past the Fast Track designation to the dilution risk embedded in that future raise.
AstraZeneca's Enhertu wins EU backing for early breast cancer
AstraZeneca (LSE:AZN) secured a second European regulatory win on the day, with the EU medicines regulator recommending Enhertu for adjuvant use in HER2-positive early breast cancer. The recommendation was backed by trial data showing a 53% reduction in disease recurrence or death compared with current standard care.
Coming alongside the Klygefa opinion, the Enhertu recommendation underlines the breadth of AstraZeneca's late-stage regulatory pipeline moving through Europe simultaneously, with shares up 0.77% at 12,596p on the day.
Coiled Therapeutics enrols two dose cohorts of new AO-252 formulation
Coiled Therapeutics (AIM:COIL) (COIL), the precision oncology company, has completed patient enrolment across two escalation cohorts of its reformulated AO-252 cancer drug, keeping the programme on track for a year-end safety readout. Shares rose 0.82% to 9.83p on the update.
The enrolment milestone keeps Coiled's timeline intact ahead of a safety data readout that will be the next material test of the reformulated asset, with the company's near-term valuation likely to hinge on whether that year-end data confirms the tolerability profile needed to advance further dose cohorts.
